

# Cobicistat Versus Ritonavir: Similar Pharmacokinetic E Differences

Annals of Pharmacotherapy

51, 1008-1022

DOI: [10.1177/1060028017717018](https://doi.org/10.1177/1060028017717018)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Variable Tacrolimus Dosing After Protease Inhibitor-Based Antiretroviral Therapy Discontinuation in 2 HIV Patients Post-Kidney Transplantation. <i>Journal of Pharmacy Technology</i> , 2018, 34, 86-88.	0.5	1
2	Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination. <i>Acta Biomaterialia</i> , 2018, 74, 344-359.	4.1	52
3	Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	6
4	HIV-1 update 2018. <i>Pharmacy Today</i> , 2018, 24, 51-69.	0.0	1
5	Darunavir&ndash;cobicistat&ndash;emtricitabine&ndash;tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3635-3643.	2.0	12
6	Symtuza® (DRV/c/FTC/TAF) en la prÁctica clÁnica. <i>Enfermedades Infecciosas Y MicrobiologÁa ClÁnica</i> , 2018, 36, 31-36.	0.3	2
7	Pharmacokinetic Enhancers (Boosters)â€”Escort for Drugs against Degrading Enzymes and Beyond. <i>Scientia Pharmaceutica</i> , 2018, 86, 43.	0.7	17
8	Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 929-934.	0.9	4
9	Pharmacokinetic Differences Between Cobicistat and Ritonavir on Warfarin. <i>Annals of Pharmacotherapy</i> , 2018, 52, 1165-1166.	0.9	2
10	Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 927-935.	1.5	19
11	Mitochondrial dysfunctions in HIV infection and antiviral drug treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 1043-1052.	1.5	10
12	Drug-drug interactions when treating HIV-related metabolic disorders. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 787-802.	1.5	6
13	Pharmacotherapeutic management of HIV in transplant patients. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1235-1250.	0.9	6
14	Semi-quantification of HIV-1 protease inhibitor concentrations in clinical samples of HIV-infected patients using a gold nanoparticle-based immunochromatographic assay. <i>Analytica Chimica Acta</i> , 2019, 1071, 86-97.	2.6	9
15	Cobicistat as a Pharmacoenhancer in Pregnancy and Postpartum: Progress to Date and Next Steps. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 779-783.	1.0	12
16	Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 417-427.	1.5	51
18	Relevance of the drugâ€”drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat. <i>Aids</i> , 2019, 33, 1100-1102.	1.0	4
19	Update on Adverse Effects of HIV Integrase Inhibitors. <i>Current Treatment Options in Infectious Diseases</i> , 2019, 11, 372-387.	0.8	51

#	ARTICLE	IF	CITATIONS
20	CE: HIV Update: An Epidemic Transformed. American Journal of Nursing, 2019, 119, 30-39.	0.2	3
21	Pharmacogenetic testing for the treatment of aspergillosis with voriconazole in two HIV-positive patients. Pharmacogenetics and Genomics, 2019, 29, 155-157.	0.7	3
22	Tolerability of Current Antiretroviral Single-Tablet Regimens. AIDS Reviews, 2019, 20, 141-149.	0.5	9
23	Factors associated with the number of drugs in darunavir/cobicistat regimens. Journal of Antimicrobial Chemotherapy, 2020, 75, 208-214.	1.3	4
24	Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 394-396.	0.7	1
25	A comprehensive review about SARS-CoV-2. Future Virology, 2020, 15, 625-648.	0.9	61
26	Cushing's syndrome due to interaction between topical betamethasone dipropionate and darunavir/cobicistat. Medicina Clínica (English Edition), 2020, 155, 466-467.	0.1	0
27	(Carbonyl)oxyalkyl linker-based amino acid prodrugs of the HIV-1 protease inhibitor atazanavir that enhance oral bioavailability and plasma trough concentration. European Journal of Medicinal Chemistry, 2020, 207, 112749.	2.6	5
28	Inhibition and induction of CYP enzymes in humans: an update. Archives of Toxicology, 2020, 94, 3671-3722.	1.9	163
29	HIV-1 Sanctuary Sites—the Role of Membrane-Associated Drug Transporters and Drug Metabolic Enzymes. AAPS Journal, 2020, 22, 118.	2.2	11
30	Interventional Pharmacoeconomics. Cancer Journal (Sudbury, Mass ), 2020, 26, 330-334.	1.0	8
31	The importance of the cut-off point for considering good adherence in diabetes. Medicina Clínica (English Edition), 2020, 155, 467-468.	0.1	0
33	Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 290-294.	0.9	3
34	Interactions of cobicistat and ritonavir in patients with HIV and its clinical consequences. Enfermedades Infecciosas Y Microbiología Clínica (English Ed ), 2020, 38, 212-218.	0.2	2
35	Cobicistat: A case of mislabelled drug-drug interaction risk?. British Journal of Clinical Pharmacology, 2020, 86, 834-836.	1.1	7
36	Tenofovir alafenamide use in pregnant and lactating women living with HIV. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 333-342.	1.5	28
37	Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value. Clinical Pharmacology and Therapeutics, 2020, 108, 487-493.	2.3	33
38	Pharmacogenomics of Antiretroviral Drug Metabolism and Transport. Annual Review of Pharmacology and Toxicology, 2021, 61, 565-585.	4.2	4

#	ARTICLE	IF	CITATIONS
39	Desirable drug-drug interactions or when a matter of concern becomes a renewed therapeutic strategy. <i>Drug Discovery Today</i> , 2021, 26, 315-328.	3.2	8
40	CNS Neurotoxicity of Antiretrovirals. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 130-143.	2.1	58
41	Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 979-987.	0.8	2
42	Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions. <i>Methods in Molecular Biology</i> , 2021, 2342, 51-88.	0.4	3
43	Risks and benefits of reducing the number of drugs to treat HIV-1 infection. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 397-409.	1.0	14
44	The pharmacokinetics and drug-drug interactions of ivermectin in <i>Aedes aegypti</i> mosquitoes. <i>PLoS Pathogens</i> , 2021, 17, e1009382.	2.1	3
45	Potential metabolic resistance mechanisms to ivermectin in <i>Anopheles gambiae</i> : a synergist bioassay study. <i>Parasites and Vectors</i> , 2021, 14, 172.	1.0	12
46	Carbon Monoxide Inhibits Cytochrome P450 Enzymes CYP3A4/2C8 in Human Breast Cancer Cells, Increasing Sensitivity to Paclitaxel. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8437-8446.	2.9	15
47	Multidomain drug delivery systems of $\beta$ -casein micelles for the local oral co-administration of antiretroviral combinations. <i>Journal of Colloid and Interface Science</i> , 2021, 592, 156-166.	5.0	16
48	Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 389-392.	0.9	6
49	Iatrogenic Cushing syndrome following lumbar medial branch block in a patient with HIV on ritonavir and darunavir. <i>Pain Management</i> , 2021, 11, 381-387.	0.7	2
50	Antiretroviral Drug Transporters and Metabolic Enzymes in Circulating Monocytes and Monocyte-Derived Macrophages of ART-Treated People Living With HIV and HIV-Uninfected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 1093-1101.	0.9	5
51	The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 292-302.	1.5	7
52	Novel Antiretroviral Therapeutic Strategies for HIV. <i>Molecules</i> , 2021, 26, 5305.	1.7	16
53	Brief Report: No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 57-60.	0.9	3
54	Protease Inhibitors. , 2021, , 139-144.		0
55	Síndrome de Cushing secundario a interacción entre dipropionato de betametasona tóxico y darunavir/cobicistat. <i>Medicina Clínica</i> , 2020, 155, 466-467.	0.3	2
56	Challenges in Biomaterial-Based Drug Delivery Approach for the Treatment of Neurodegenerative Diseases: Opportunities for Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2021, 22, 138.	1.8	23

#	ARTICLE	IF	CITATIONS
57	Co-treatment of Tuberculosis and HIV: Pharmacologic Considerations. , 2019, , 239-267.		0
58	Confirmation of the Drug-drug Interaction Potential between Cobicistat-boosted Antiretroviral Regimens and Hormonal Contraceptives. <i>Antiviral Therapy</i> , 2019, 24, 557-566.	0.6	6
59	Interacciones de cobicistat y ritonavir en pacientes con VIH y sus consecuencias clínicas. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 212-218.	0.3	4
60	Treatment Duration with Antiretroviral Therapy and Selected Liver Enzymes among HIV Positive Patients. <i>Asian Journal of Scientific Research</i> , 2020, 14, 24-31.	0.3	1
61	Iatrogenic Cushing Syndrome In An Hiv-Infected Patient Secondary to Concomitant Therapy With Genvoya and Epidural Triamcinolone. <i>AACE Clinical Case Reports</i> , 2020, 6, e217-e220.	0.4	1
62	Improvement of the value of antiviral drugs with the use of Pharmacokinetic booster: Drug Delivery System, 2020, 35, 394-400.	0.0	1
63	Principles of HIV Treatment. , 2022, , 391-413.		0
64	A rare complication of coronary vasospasm associated with concomitant use of ergotamine, cobicistat, and darunavir. <i>Antiviral Therapy</i> , 2022, 27, 135965352110689.	0.6	1
65	Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan. <i>PLoS ONE</i> , 2022, 17, e0269779.	1.1	0
66	Interaction of CYP3A4 with Rationally Designed Ritonavir Analogues: Impact of Steric Constraints Imposed on the Heme-Ligating Group and the End-Pyridine Attachment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7291.	1.8	3
67	Real-world medication persistence among HIV-1 patients initiating integrase inhibitor-based antiretroviral therapy in Japan. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1464-1470.	0.8	4
68	Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2022, 162, 1360-1372.	0.4	10
69	Discovery of benzyloxyphenyl- and phenethylphenyl-imidazole derivatives as a new class of antiretroviral drug type boosters. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 72, 128868.	1.0	1
70	Improving Drug Delivery While Tailoring Prodrug Activation to Modulate $C_{max}$ and $C_{min}$ by Optimization of (Carbonyl)oxyalkyl Linker-Based Prodrugs of Atazanavir. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 11150-11176.	2.9	1
71	Atorvastatin Efficacy in the Management of Mild to Moderate Hospitalized COVID-19: A Pilot Randomized Triple-blind Placebo- controlled Clinical Trial. <i>Recent Advances in Anti-Infective Drug Discovery</i> , 2022, 17, 212-222.	0.4	11
72	Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects. <i>Xenobiotica</i> , 2022, 52, 541-554.	0.5	1
73	Impact of Paxlovid on international normalized ratio among patients on chronic warfarin therapy. <i>Blood</i> , 2022, 140, 2757-2759.	0.6	2
74	Pharmacokinetic Boosting of Kinase Inhibitors. <i>Pharmaceutics</i> , 2023, 15, 1149.	2.0	4

#	ARTICLE	IF	CITATIONS
75	The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114636.	2.5	6
76	Open-label, drug-drug interaction study between the HIV-1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 2236-2245.	1.1	2
77	Cytochrome P450 and Other Drug-Metabolizing Enzymes As Therapeutic Targets. <i>Drug Metabolism and Disposition</i> , 2023, 51, 936-949.	1.7	3
85	Cytochrome P450 (inhibitors for the metabolism of drugs). , 2024, , 449-457.		0